A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 242 participants.

Also called NCT03226899

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03226899
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Poland (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03226899. Randomized; triple masking; primary purpose treatment. Start 2017-07-19 (actual); primary completion 2019-02-25 (actual). Results posted on 2021-11-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Condition
Gout
Intervention (Drug)
Lesinurad
Intervention (Drug)
XOI
Intervention (Drug)
Placebo
Intervention (Drug)
colchicine
Intervention (Drug)
corticosteroids
Lead sponsor
Ironwood Pharmaceuticals, Inc. (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03226899
Content hash
fa750549ae307b7ef35207f978fcd97bb1fa2f59d824569a774ec723b48f576a